| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8443940 | European Journal of Cancer | 2013 | 8 Pages |
Abstract
Regorafenib had acceptable tolerability and evidence of antitumour activity in patients with intermediate or advanced HCC that progressed following first-line sorafenib.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Jordi Bruix, Won-Young Tak, Antonio Gasbarrini, Armando Santoro, Massimo Colombo, Ho-Yeong Lim, Vincenzo Mazzaferro, Reiner Wiest, MarÃa Reig, Andrea Wagner, Luigi Bolondi,